RU2227042C2 - Композиции и способы системной доставки пероральных вакцин и терапевтических агентов - Google Patents

Композиции и способы системной доставки пероральных вакцин и терапевтических агентов Download PDF

Info

Publication number
RU2227042C2
RU2227042C2 RU2000112547/15A RU2000112547A RU2227042C2 RU 2227042 C2 RU2227042 C2 RU 2227042C2 RU 2000112547/15 A RU2000112547/15 A RU 2000112547/15A RU 2000112547 A RU2000112547 A RU 2000112547A RU 2227042 C2 RU2227042 C2 RU 2227042C2
Authority
RU
Russia
Prior art keywords
botulinum toxin
modified botulinum
oral
modified
modifying
Prior art date
Application number
RU2000112547/15A
Other languages
English (en)
Russian (ru)
Other versions
RU2000112547A (ru
Inventor
Лэнс СИМПСОН (US)
Лэнс СИМПСОН
Никита КИЯТКИН (US)
Никита КИЯТКИН
Эндрю МАКСИМОВИЧ (US)
Эндрю МАКСИМОВИЧ
Original Assignee
Томас Джефферсон Юниверсити
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Томас Джефферсон Юниверсити filed Critical Томас Джефферсон Юниверсити
Publication of RU2000112547A publication Critical patent/RU2000112547A/ru
Application granted granted Critical
Publication of RU2227042C2 publication Critical patent/RU2227042C2/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/832—Drug, bio-affecting and body treating compositions involving bacterial toxin that has modified amino acid sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
RU2000112547/15A 1997-10-20 1998-10-16 Композиции и способы системной доставки пероральных вакцин и терапевтических агентов RU2227042C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/954,302 US6051239A (en) 1997-10-20 1997-10-20 Compositions and methods for systemic delivery of oral vaccines and therapeutic agents
US08/954,302 1997-10-20

Publications (2)

Publication Number Publication Date
RU2000112547A RU2000112547A (ru) 2002-05-20
RU2227042C2 true RU2227042C2 (ru) 2004-04-20

Family

ID=25495232

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2000112547/15A RU2227042C2 (ru) 1997-10-20 1998-10-16 Композиции и способы системной доставки пероральных вакцин и терапевтических агентов

Country Status (16)

Country Link
US (1) US6051239A (enExample)
EP (1) EP1024827B1 (enExample)
JP (1) JP2001522783A (enExample)
KR (1) KR100594787B1 (enExample)
CN (1) CN1246038C (enExample)
AT (1) ATE355076T1 (enExample)
AU (1) AU756475B2 (enExample)
BR (1) BR9815255A (enExample)
CA (1) CA2306995A1 (enExample)
DE (1) DE69837209T2 (enExample)
EE (1) EE200000536A (enExample)
HU (1) HUP0101017A3 (enExample)
IL (1) IL135743A (enExample)
NZ (1) NZ504549A (enExample)
RU (1) RU2227042C2 (enExample)
WO (1) WO1999020306A1 (enExample)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7227010B2 (en) 1993-09-21 2007-06-05 United States Of America As Represented By The Secretary Of The Army Recombinant light chains of botulinum neurotoxins and light chain fusion proteins for use in research and clinical therapy
US6967088B1 (en) * 1995-03-16 2005-11-22 Allergan, Inc. Soluble recombinant botulinum toxin proteins
US8632785B2 (en) * 2000-02-08 2014-01-21 Allergan, Inc. Clostridial toxin pharmaceutical composition containing a gelatin fragment
KR100753765B1 (ko) * 2000-02-08 2007-08-31 알레간 인코포레이티드 보툴리눔 독소 약제학적 조성물
US7780967B2 (en) * 2000-02-08 2010-08-24 Allergan, Inc. Reduced toxicity Clostridial toxin pharmaceutical compositions
US20030118598A1 (en) * 2000-02-08 2003-06-26 Allergan, Inc. Clostridial toxin pharmaceutical compositions
US20060269575A1 (en) * 2000-02-08 2006-11-30 Allergan, Inc. Botulinum toxin pharmaceutical compositions formulated with recombinant albumin
US6903187B1 (en) * 2000-07-21 2005-06-07 Allergan, Inc. Leucine-based motif and clostridial neurotoxins
AU2002228887B2 (en) * 2000-11-06 2006-08-24 United States Army Medical Research And Material Command Recombinant light chains of botulinum neurotoxins and light chain fusion proteins for use in research and clinical therapy
US7273722B2 (en) * 2000-11-29 2007-09-25 Allergan, Inc. Neurotoxins with enhanced target specificity
JP4707254B2 (ja) * 2001-04-24 2011-06-22 クミアイ化学工業株式会社 粒状組成物及びその製造方法
US7691394B2 (en) * 2002-05-28 2010-04-06 Botulinum Toxin Research Associates, Inc. High-potency botulinum toxin formulations
AU2003237346A1 (en) * 2002-05-31 2003-12-19 Thomas Jefferson University Compositions and methods for transepithelial molecular transport
US20040086532A1 (en) * 2002-11-05 2004-05-06 Allergan, Inc., Botulinum toxin formulations for oral administration
EP1629090B1 (en) * 2002-11-06 2014-03-05 iBio, Inc. Expression of foreign sequences in plants using trans-activation system
US7491509B2 (en) 2003-02-03 2009-02-17 Fraunhofer Usa, Inc. System for expression of genes in plants
US7683238B2 (en) * 2002-11-12 2010-03-23 iBio, Inc. and Fraunhofer USA, Inc. Production of pharmaceutically active proteins in sprouted seedlings
US7692063B2 (en) * 2002-11-12 2010-04-06 Ibio, Inc. Production of foreign nucleic acids and polypeptides in sprout systems
AU2003300666A1 (en) * 2002-12-20 2004-07-29 Botulinum Toxin Research Associates, Inc. Pharmaceutical botulinum toxin compositions
US20040253274A1 (en) * 2003-06-11 2004-12-16 Allergan, Inc. Use of a clostridial toxin to reduce appetite
US7172764B2 (en) * 2003-11-17 2007-02-06 Allergan, Inc. Rescue agents for treating botulinum toxin intoxications
US20050129677A1 (en) * 2003-12-10 2005-06-16 Shengwen Li Lipid rafts and clostridial toxins
AU2005216133A1 (en) * 2004-02-20 2005-09-09 Fraunhofer Usa, Inc. Systems and methods for clonal expression in plants
US7306807B2 (en) 2004-09-13 2007-12-11 Wyeth Hemorrhagic feline calicivirus, calicivirus vaccine and method for preventing calicivirus infection or disease
US7785606B2 (en) * 2004-11-22 2010-08-31 New York University Genetically engineered clostridial genes, proteins encoded by the engineered genes, and uses thereof
JP4667507B2 (ja) 2005-10-07 2011-04-13 ファイザー・プロダクツ・インク イヌインフルエンザを治療するワクチンおよび方法
EP1931379B1 (en) 2005-10-07 2013-05-29 Health Protection Agency Proteins with improved solubility and methods for producing and using same
US20080299149A1 (en) * 2007-05-30 2008-12-04 Wyeth Raccoon Poxvirus Expressing Genes of Feline Antigens
US8445650B2 (en) * 2007-09-25 2013-05-21 Thomas Jefferson University Mutant botulinum neurotoxin serotype A polypeptide and uses thereof
WO2010096134A1 (en) 2008-12-04 2010-08-26 Botulinum Toxin Research Associates, Inc. Extended length botulinum toxin formulation for human or mammalian use
US9393291B2 (en) 2012-04-12 2016-07-19 Botulinum Toxin Research Associates, Inc. Use of botulinum toxin for the treatment of cerebrovascular disease, renovascular and retinovascular circulatory beds
EP2948174B1 (en) 2013-01-28 2019-09-11 New York University Treatment methods using atoxic neurotoxin derivatives
US9901627B2 (en) 2014-07-18 2018-02-27 Revance Therapeutics, Inc. Topical ocular preparation of botulinum toxin for use in ocular surface disease
US11484580B2 (en) 2014-07-18 2022-11-01 Revance Therapeutics, Inc. Topical ocular preparation of botulinum toxin for use in ocular surface disease
EP3230457B1 (en) 2014-12-09 2021-06-30 New York University Clostridial neurotoxin fusion proteins, propeptide fusions, their expression, and use
BR112020012641A2 (pt) 2017-12-20 2020-12-01 Allergan, Inc. polipeptídeos de domínio de ligação celular de toxina de botulinum e métodos de uso para rejuvenescimento da pele

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997032599A1 (en) * 1996-03-08 1997-09-12 The Regents Of The University Of California Chemically-modified clostridiatoxin with improved properties

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5919665A (en) * 1989-10-31 1999-07-06 Ophidian Pharmaceuticals, Inc. Vaccine for clostridium botulinum neurotoxin
AU695623B2 (en) * 1994-05-31 1998-08-20 Allergan, Inc. Modification of clostridial toxins for use as transport proteins
EP0796326A4 (en) * 1994-10-24 2000-01-19 Ophidian Pharm Inc VACCINE AND ANTITOXIN FOR THE TREATMENT AND PREVENTION OF C. DIFFICILE DISEASE
WO1996040229A1 (en) * 1995-06-07 1996-12-19 Thomas Jefferson University Vaccines synthesized by transgenic plants

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997032599A1 (en) * 1996-03-08 1997-09-12 The Regents Of The University Of California Chemically-modified clostridiatoxin with improved properties

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ZHOU et al. Expression and purification of the hight chain of botulinum neurotoxin A; a single mutation abolish its clevage of SNAP-25 and neurotoxicity after reconstitution with heavy chain. Biochemistry. - 1995, v. 34, p. 15174-15181. FERRER-MONTIEL et al. Phosphorylation modulators the activity of clostridial neurotoxins. J. Biol. Chem. - 1996, v. 271, N 1, p. 18322-18325. *

Also Published As

Publication number Publication date
DE69837209T2 (de) 2007-10-31
HUP0101017A3 (en) 2003-11-28
HUP0101017A2 (hu) 2001-07-30
EP1024827B1 (en) 2007-02-28
IL135743A (en) 2004-03-28
CN1290174A (zh) 2001-04-04
WO1999020306A1 (en) 1999-04-29
BR9815255A (pt) 2001-12-26
DE69837209D1 (de) 2007-04-12
US6051239A (en) 2000-04-18
EP1024827A4 (en) 2002-08-28
EE200000536A (et) 2002-04-15
IL135743A0 (en) 2001-05-20
ATE355076T1 (de) 2006-03-15
EP1024827A1 (en) 2000-08-09
JP2001522783A (ja) 2001-11-20
AU756475B2 (en) 2003-01-16
CN1246038C (zh) 2006-03-22
CA2306995A1 (en) 1999-04-29
KR20010031236A (ko) 2001-04-16
NZ504549A (en) 2002-12-20
KR100594787B1 (ko) 2006-07-03
AU1094799A (en) 1999-05-10

Similar Documents

Publication Publication Date Title
RU2227042C2 (ru) Композиции и способы системной доставки пероральных вакцин и терапевтических агентов
RU2000112547A (ru) Композиции и способы системной доставки пероральных вакцин и терапевтических агентов
ES2569949T3 (es) Formulaciones farmacéuticas que comprenden un péptido complejado con una dicetopiperazina
FI971776A0 (fi) Yhdisteet ja koostumukset aktiivisten aineiden antamiseksi
WO1994008551A3 (en) Pharmaceutical compositions and methods for treating cold symptoms
SE9301489D0 (sv) Veterinary composition
NO942155D0 (no) Legemiddelformuleringer for parenteral anvendelse
EP1226109A4 (en) PHENYLAMINE CARBOXYLIC ACID COMPOUNDS AND COMPOSITIONS FOR DISPENSING ACTIVE AGENTS
NO964527L (no) Blandinger omfattende DNA-ödeleggende midler og P53
DE69213010D1 (de) Verwendung eines Bakteriozin antibiotischen Agenten zur Herstellung eines Arzneimittels zur Behandlung von Magenverstimmungen, die durch Helicobacter pylori verursacht werden.
MA23344A1 (fr) Nouvelles compositions d'emulsions
NO20000378D0 (no) Anvendelse av MHC klasse II ligander som adjuvantia for vaksinasjon og LAG-3 i kreftbehandling
DE69434121D1 (de) Pharmazeutische zusammensetzung zur immunstimulierenden therapie
AU7814498A (en) Multivalent (in ovo) avian vaccine
BG106221A (bg) Назални фармацевтични препарати съдържащи морфин и методи на приложението им
DE60239752D1 (de) Den geschmack verdeckende auslaufsichere formulierung
IS7296A (is) Bóluefni og aðferð við meðhöndlun á hreyfitaugungahrörnun
ATE215381T1 (de) Pharmazeutische nichtinorganische salzlösungen für endonasale verabreichung eines calcitonins
MXPA02005563A (es) Formulacion estable de interferon en solucion acuosa, metodo de preparacion y usos de la misma.
DK0996462T3 (da) Farmaceutiske kombinationspræparater indeholdende erythropoietin og modificerede hæmoglobiner
DK0684812T3 (da) Kondenseret-fase mikropartikel-præparat og fremgangsmåde
EP1037918A4 (en) METHOD AND COMPOSITIONS FOR INCREASING THE EFFICIENCY OF VACCINALS USING CHEMOKINES
BG103905A (en) New bpc peptide salts with organoprotective activity, method for their preparation and application in medicine
DE69902925D1 (de) Ramoplaninhaltige neue injizierbare arzneizubereitungen
EP0790250A3 (en) Inhibitors of biogenic amine transporters

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20071017